Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity

Kobayashi, Hisataka; Furusawa, Aki; Rosenberg, Adrian; Choyke, Peter L.

doi:10.1093/intimm/dxaa037

Cited by 102 publications

(93 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When exposed to NIR light, Akalux induces a highly selective and rapid necrotic/immunogenic cell death (ICD) only in target-positive cells. The ICD occurs as early as 1 min after exposure to NIR light, but immediately adjacent target-negative cells are unharmed [ 66 ]. ICD induced by NIR-PIT promoted maturation of immature dendritic cells (DCs) to maturated DCs that primed cytotoxic T-cells to react with cancer-related antigens released from destroyed cancer cells [ 66 ].…”

Section: Photoimmunotherapy In Hnsccmentioning

confidence: 99%

Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

Kitamura

Sento

Yoshizawa

et al. 2020

IJMS

152

View full text Add to dashboard Cite

In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.

show abstract

Section: Photoimmunotherapy In Hnsccmentioning

confidence: 99%

Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

Kitamura

Sento

Yoshizawa

et al. 2020

IJMS

152

View full text Add to dashboard Cite

show abstract

“…In this context, several formulations with fluorophores/PSs conjugated to tumortargeted molecules have been developed to improve specificity [195,196]. Advances in the generation and biological use of therapeutic mAbs and technologies pertaining to the synthesis of antibody-drug conjugates have led to the development of several targeted PS conjugates (referred as photo-immunoconjugates; PICs) for image-guided surgeries and targeted PDT (more specifically referred to as photo-immunotherapy; PIT) [65,[197][198][199][200]. While PFD associated with PICs can be exploited to identify tumor margins during surgical resection and possibly detection of occult metastases, subsequent PIT of the resected tumor bed may assist in the treatment of residual microscopic tumor [201,202], as discussed below.…”

Section: Optical Imaging For Diagnostics and Therapy Guidance In Pdt mentioning

confidence: 99%

Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization — a Thomas Dougherty Award for Excellence in PDT paper

Silva

Saad

Thomsen

et al. 2020

J. Porphyrins Phthalocyanines

View full text Add to dashboard Cite

Photodynamic therapy is a photochemistry-based approach, approved for the treatment of several malignant and non-malignant pathologies. It relies on the use of a non-toxic, light activatable chemical, photosensitizer, which preferentially accumulates in tissues/cells and, upon irradiation with the appropriate wavelength of light, confers cytotoxicity by generation of reactive molecular species. The preferential accumulation however is not universal and, depending on the anatomical site, the ratio of tumor to normal tissue may be reversed in favor of normal tissue. Under such circumstances, control of the volume of light illumination provides a second handle of selectivity. Singlet oxygen is the putative favorite reactive molecular species although other entities such as nitric oxide have been credibly implicated. Typically, most photosensitizers in current clinical use have a finite quantum yield of fluorescence which is exploited for surgery guidance and can also be incorporated for monitoring and treatment design. In addition, the photodynamic process alters the cellular, stromal, and/or vascular microenvironment transiently in a process termed photodynamic priming, making it more receptive to subsequent additional therapies including chemo- and immunotherapy. Thus, photodynamic priming may be considered as an enabling technology for the more commonly used frontline treatments. Recently, there has been an increase in the exploitation of the theranostic potential of photodynamic therapy in different preclinical and clinical settings with the use of new photosensitizer formulations and combinatorial therapeutic options. The emergence of nanomedicine has further added to the repertoire of photodynamic therapy’s potential and the convergence and co-evolution of these two exciting tools is expected to push the barriers of smart therapies, where such optical approaches might have a special niche. This review provides a perspective on current status of photodynamic therapy in anti-cancer and anti-microbial therapies and it suggests how evolving technologies combined with photochemically-initiated molecular processes may be exploited to become co-conspirators in optimization of treatment outcomes. We also project, at least for the short term, the direction that this modality may be taking in the near future.

show abstract

“…The important distinction between type I (oxygen radical) and type II (singlet oxygen) reactions, and the importance of type II reactions in photochemistry, was clearly established by Foote (Foote, 1991;Greer, 2006); subsequent work has confirmed this [examples: (Doria et al, 2013;Ashen-Garry and Selke, 2014;Baptista et al, 2017)]. Singlet oxygen production by photosensitizers (PS) has been used for photoactive antiviral drugs (Vigant et al, 2013), for induction of apoptosis or necrosis (Bauer, 2016;Kessel, 2019a), and for generation of cytotoxic or immune-inducing signals in photodynamic tumor ablation (Turan et al, 2016;Kobayashi et al, 2020). The drawbacks of traditional PSs [e.g.…”

Section: Introductionmentioning

confidence: 99%

Subcellular Singlet Oxygen and Cell Death: Location Matters

et al. 2020

View full text Add to dashboard Cite

We developed a tool for targeted generation of singlet oxygen using light activation of a genetically encoded fluorogen-activating protein complexed with a unique dye molecule that becomes a potent photosensitizer upon interaction with the protein. By targeting the protein receptor to activate this dye in distinct subcellular locations at consistent per-cell concentrations, we investigated the impact of localized production of singlet oxygen on induction of cell death. We analyzed light dose-dependent cytotoxic response and characterized the apoptotic vs. necrotic cell death as a function of subcellular location, including the nucleus, the cytosol, the endoplasmic reticulum, the mitochondria, and the membrane. We find that different subcellular origins of singlet oxygen have different potencies in cytotoxic response and the pathways of cell death, and we observed that CT26 and HEK293 cell lines are differentially sensitive to mitochondrially localized singlet oxygen stresses. This work provides new insight into the function of type II reactive oxygen generating photosensitizing processes in inducing targeted cell death and raises interesting mechanistic questions about tolerance and survival mechanisms in studies of oxidative stress in clonal cell populations.

show abstract

Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity

Cited by 102 publications

References 76 publications

Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization — a Thomas Dougherty Award for Excellence in PDT paper

Subcellular Singlet Oxygen and Cell Death: Location Matters

Contact Info

Product

Resources

About